Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053090 | 0.82 | AVPR2 (0.32) | AVPR2AVPR1AADORA2B | |
| SCHEMBL859620 | 0.74 | — | — | |
| SCHEMBL27364397 | 0.74 | — | — | |
| SCHEMBL10926533 | 0.73 | NPSR1 (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL9497797 | 0.72 | ADORA2B (0.33) | CYP11B1CYP11B2ADORA2B | |
| SCHEMBL5779690 | 0.72 | — | — | |
| Iodide SCHEMBL27303018 | 0.72 | CYP19A1 (0.41) | CYP11B1CYP11B2ADORA2B | |
| SCHEMBL5391398 | 0.71 | CYP11B1 (0.45) | CYP11B1CYP11B2ADORA2B | |
| Hydrochloric Acid SCHEMBL9443719 | 0.71 | ADORA2B (0.32) | CYP11B1CYP11B2ADORA2B | |
| SCHEMBL7247430 | 0.71 | CYP11B1 (0.46) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039467-A1 | Ionic liquid flame retardants | H&C Chemical (US) | 2011-02-17 | — | — | US | disclosed |
| US-6630593-B1 | A process for preparing a 1-substituted 5-hydroxymethylimidazole of the formula: wherein R represents alkyl, hydroxyalkyl, allyl, or substituted or unsubstituted arylmethyl or diarylmethyl, comprising the step of reacting a | LG CHEM INVESTMENT LTD. (KR) | 2003-10-07 | — | — | US | disclosed |
| EP-1255737-A4 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG CHEM INVESTMENT LTD (KR) | 2003-04-16 | — | — | EP | disclosed |
| EP-1255737-A1 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG Chem Investment, Ltd. (KR) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001017974-A1 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG CHEM INVESTMENT LTD. (KR) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039467-A1 | Ionic liquid flame retardants | L3MBTL4, AFF4, L3MBTL3 | CYP11B1 2276/4885CYP11B2 2359/4885AVPR2 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.